Lista de obras -

A proteomic analysis of pediatric seizure cases associated with astrocytic inclusions ⬇️

artículo científico publicado el 5 de enero de 2012

AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease

artículo científico publicado en 2017

Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers

artículo científico publicado en 2018

Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats

artículo científico publicado en 2006

Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker

artículo científico

Author response

artículo científico publicado en 2015

Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities

artículo científico publicado en 2019

Chronic pre-treatment with nicotine enhances nicotine-evoked striatal dopamine release and alpha6 and beta3 nicotinic acetylcholine receptor subunit mRNA in the substantia nigra pars compacta of the rat.

artículo científico publicado en 2005

Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study

artículo científico publicado en 2018

Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease

artículo científico publicado en 2015

Dendritic spine density is altered in a mouse model of Cockayne syndrome.

artículo científico publicado en 2013

Dietary resveratrol administration increases MnSOD expression and activity in mouse brain.

artículo científico publicado en 2008

Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.

artículo científico publicado en 2008

Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease

artículo científico publicado en 2006

Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes.

artículo científico publicado en 2011

Gastrointestinal dysfunction in Parkinson's disease

artículo científico publicado en 2015

Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease

artículo científico publicado en 2017

Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease

artículo científico publicado en 2006

Identifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology

artículo científico publicado en 2020

Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations

artículo científico publicado en 2010

Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease

artículo científico publicado en 2012

Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease

scientific article published on 23 August 2019

Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson’s Disease

artículo científico publicado en 2018

Iron deficiency in parkinsonism: region-specific iron dysregulation in Parkinson's disease and multiple system atrophy.

artículo científico publicado en 2013

Lymphatic vasculature in human dural superior sagittal sinus: Implications for neurodegenerative proteinopathies

artículo científico publicado en 2017

MPTP‐Induced Models of Parkinson's Disease in Mice and Non‐Human Primates ⬇️

artículo científico publicado el 1 de julio de 2005

Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease.

artículo científico publicado en 2010

Novel transgenic technology reveals several molecular adaptations and potential therapeutic targets in the direct pathway in levodopa-induced dyskinesia

artículo científico publicado en 2014

PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease.

artículo científico publicado en 2008

Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease

artículo científico publicado en 2006

Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease.

artículo científico publicado en 2008

Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson's disease

scientific article published on 14 May 2018

Reply to: Gray et al

artículo científico publicado en 2014

Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease

scientific article published on 01 June 2018

Synchrotron XRF imaging of Alzheimer's disease basal ganglia reveals linear dependence of high-field magnetic resonance microscopy on tissue iron concentration

artículo científico publicado en 2019

The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease

artículo científico publicado en 2008

The prion hypothesis in Parkinson's disease: Braak to the future

artículo científico publicado en 2013

The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration.

artículo científico publicado en 2002

Tumor Necrosis Factor-α Underlies Loss of Cortical Dendritic Spine Density in a Mouse Model of Congestive Heart Failure

artículo científico publicado en 2015

Using artificial intelligence to identify anti-hypertensives as possible disease modifying agents in Parkinson's disease

artículo científico publicado en 2020

α-Synuclein membrane association is regulated by the Rab3a recycling machinery and presynaptic activity.

artículo científico publicado en 2013

α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.

artículo científico publicado en 2016

Lista de obras de

A proteomic analysis of pediatric seizure cases associated with astrocytic inclusions ⬇️

AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease

Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers

Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats

Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker

Author response

Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities

Chronic pre-treatment with nicotine enhances nicotine-evoked striatal dopamine release and alpha6 and beta3 nicotinic acetylcholine receptor subunit mRNA in the substantia nigra pars compacta of the rat.

Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study

Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease

Dendritic spine density is altered in a mouse model of Cockayne syndrome.

Dietary resveratrol administration increases MnSOD expression and activity in mouse brain.

Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.

Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease

Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes.

Gastrointestinal dysfunction in Parkinson's disease

Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease

Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease

Identifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology

Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations

Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease

Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease

Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson’s Disease

Iron deficiency in parkinsonism: region-specific iron dysregulation in Parkinson's disease and multiple system atrophy.

Lymphatic vasculature in human dural superior sagittal sinus: Implications for neurodegenerative proteinopathies

MPTP‐Induced Models of Parkinson's Disease in Mice and Non‐Human Primates ⬇️

Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease.

Novel transgenic technology reveals several molecular adaptations and potential therapeutic targets in the direct pathway in levodopa-induced dyskinesia

PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease.

Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease

Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease.

Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson's disease

Reply to: Gray et al

Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease

Synchrotron XRF imaging of Alzheimer's disease basal ganglia reveals linear dependence of high-field magnetic resonance microscopy on tissue iron concentration

The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease

The prion hypothesis in Parkinson's disease: Braak to the future

The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration.

Tumor Necrosis Factor-α Underlies Loss of Cortical Dendritic Spine Density in a Mouse Model of Congestive Heart Failure

Using artificial intelligence to identify anti-hypertensives as possible disease modifying agents in Parkinson's disease

α-Synuclein membrane association is regulated by the Rab3a recycling machinery and presynaptic activity.

α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.